About Us
Contact Us
ImmuOn Therapeutics Ltd.
Address: The Chenqiao BridgePark, 12F 188 Yongchang road, Gangzha District, Nantong City, Jiangsu Province
Phone: 86-513-55881566-801
Fax:86-513-55881566-802
 
首页 > English > About Us > ManagementManagement
1.jpg
Dr. John Wang, Chairman and CEO
Dr. Wang has 25 years’ experiences in biotech and pharmaceutical industry R&D including start-ups, mid-size and multinational pharmaceutical corporations. Dr. Wang was graduated from China Pharmaceutical University, China and received PhD in Pharmacology from Mario Institute of Pharmacological Research, Italy and postdoc training at University of Arizona at Tuson, US. With a background in molecular pharmacology, Dr. Wang has experience in developing both small molecule drug and biologicals including mAbs and vaccines. He has led research groups in epitope mapping, monoclonal antibody generation, as well as in drug screening, lead optimization and profiling, including early ADME in the areas of CNS, diabetics, infectious diseases and cancer. Dr. Wang has broad connection with international biopharmaceutical professional community. He was elected twice to the Board Director and Vice-President of the Society for Biomolecule Sciences (SBS, now SLAS) to promote the science and technology of drug discovery. He co-founded the Chinese American Biopharmaceutical Society now with over 3000 members in the Greater San Francisco area. Meanwhile, he established and served for 5 years as the Editor-in-Chief of 《Trends in Biopharmaceutical Industry》, a scientific journal published with collaboration of five Chinese-American professional societies in US. Currently, he is the co-founder of the Linkedin society of China Biotechnology & Pharmaceutical Association with over 3000 members.

 

 
4.jpg
Dr. Ying Peng. VP of Process
Dr. Peng has over 20 years’ experience in developing and manufacturing biologicals. Dr. Peng graduated from China Pharmaceutical received his PhD from Beijing Union University, China and postdoc training from UC San Diego, USA. Dr. Peng has worked with CNBI International Inc. and Merck KGaA’s EMD Biosciences Inc. as senior scientist, head of QA/QC, Head of New Product Development and Head of China, incrementally. During his career, he had led projects in protein expression, monoclonal antibody and vaccine productions. Dr. Peng is a National “1000Plan” expert.

 

 

图片1.jpg
Dr. Arthur Young, CTO
Dr. Arthur Young graduated from the University of California, Berkeley, majoring in immunology. He received his PhD in Cell and Molecular Biology from University of Washington. He has conducted postdoc research in Dana Farber Cancer Institute of Harvard Medical School and the University of California, Los Angeles, to study viruses, cancer and aging. Dr. Yang has long been engaged in the research of influenza virus and hepatitis B virusresearch, and is the inventor of broad-spectrum influenza vaccine.

 

图片2.jpg
John Lin MS, MBA, VP, BD
Dr. Lin graduated from the School of Pharmacy of Fudan University, and received his master's degree from Peking Union Medical University and the Chinese Institute of Laboratory Medicine. He later received MBA from the University of Houston. He had worked at Louisiana University, M.D. Anderson Cancer Center of the University of Texas, and Houston Medical College.
Dr. Lin has many years of experience in biomedical research and technology development, as well as technology transfer of scientific research, product commercialization and market development. He has participated in the establishment and management of a number of Sino-US high-tech and investment companies and was the managing director of an institutional investors consulting companies.

 

Higene Discovery
Copyright © ImmuOn Therapeutics Ltd. Address: The Chenqiao BridgePark, 12F 188 Yongchang road, Gangzha District, Nantong City, Jiangsu Province China, 226003
Phone:86-513-55881566-801 Fax:86-513-55881566-802 Email:info@immuon.com